Carla Vidaurre_Agut

Mrs. Carla Vidaurre_Agut

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
EBEva María Rivero Buceta
Eva María Rivero Buceta
ABAdrián Bernal-Gómez
Adrián Bernal-Gómez
CVCarla Vidaurre_Agut
Carla Vidaurre_Agut
EMEric Lopez Moncholi
Eric Lopez Moncholi
JBJose María Benlloch
Jose María Benlloch
Pablo Botella AsuncionPablo Botella Asuncion
Pablo Botella Asuncion
Docetaxel (DTX) is a recommended treatment in patients with metastasic prostate cancer (PCa), despite its therapeutic efficacy is limited by strong systemic toxicity. However, in localized PCa, intratumoral (IT) administration of DTX could be an alternative to consider that may help to overcome the disadvantages of conventional intravenous (IV) therapy. In this context, we here present the first in vivo preclinical study of PCa therapy with nanomedicines of mesoporous silica nanoparticles (MSN) and DTX by IT injection over a xenograft mouse model bearing human prostate adenocarcinoma tumors. The efficacy and tolerability, the biodistribution and the histopathology after therapy have been investigated for the DTX nanomedicine and the free drug, and compared with the IV administration of DTX. The obtained results demonstrate that IT injection of DTX and DTX nanomedicines allows precise and selective therapy of non-metastatic PCa and minimize systemic diffusion of the drug, showing superior activity than IV route. This allows reducing the therapeutic dose by one order and widens substantially the therapeutic window for this drug. Furthermore, the use of DTX nanomedicines as IT injection promotes strong antitumor efficacy and drug accumulation at the tumor site, improving the results obtained with the free drug by the same route.

18 November 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Pablo Botella AsuncionPablo Botella Asuncion
Pablo Botella Asuncion
EREva M. Rivero-Buceta
Eva M. Rivero-Buceta
CVCarla Vidaurre_Agut
Carla Vidaurre_Agut
RLRaquel Lama López
Raquel Lama López
MRMagalí Rey-Campos
Magalí Rey-Campos
JBJose María Benlloch
Jose María Benlloch
An archetypal anti-inflammatory compound against cytokine storm would inhibit it without suppressing the innate immune response. AG5, an anti-inflammatory compound, has been developed as synthetic derivative of andrographolide, which is highly absorbable and presents low toxicity. We found that the mechanism of action of AG5 is through the inhibition of caspase-1. Interestingly, we show with in vitro generated human monocyte derived dendritic cells that AG5 preserves innate immune response. AG5 minimizes inflammatory response in a mouse model of lipopolysaccharide (LPS)-induced lung injury and exhibits in vivo anti-inflammatory efficacy in the SARS-CoV-2-infected mouse model. AG5 opens up a new class of anti-inflammatories, since contrary to NSAIDs, AG5 is able to inhibit the cytokine storm, like dexamethasone, but, unlike corticosteroids, preserves adequately the innate immunity. This is critical at the early stages of any naïve infection, but particularly in SARS-CoV-2 infections. Furthermore, AG5 showed interesting antiviral activity against SARS-CoV-2 in humanized mice.

22 April 2025 in Microporous and Mesoporous Materials
Verified
Journal Article
Open access
LGLucía Gómez
Lucía Gómez
EBEva María Rivero Buceta
Eva María Rivero Buceta
CVCarla Vidaurre_Agut
Carla Vidaurre_Agut
Pablo Botella AsuncionPablo Botella Asuncion
Pablo Botella Asuncion

1 May 2021 in Nanomaterials
Verified
Journal Article
Open access
PDF file
CVCarla Vidaurre_Agut
Carla Vidaurre_Agut
EBEva María Rivero Buceta
Eva María Rivero Buceta
CLChristopher C. Landry
Christopher C. Landry
Pablo Botella AsuncionPablo Botella Asuncion
Pablo Botella Asuncion
To understand the factors that control the formation of the biomolecular corona, a systematic study of the adsorption of several miRNAs shown to be important in prostate cancer on amine-functionalized mesoporous silica nanoparticles (MSN-NH2) has been performed. Process parameters including miRNA type, nanoparticle concentration, incubation temperature and incubation time were investigated, as well as the potential competition for adsorption between different miRNA molecules. The influence of proteins and particle PEGylation on miRNA adsorption were also explored. We found that low particle concentrations and physiological temperature both led to increased miRNA adsorption. Adsorption of miRNA was also higher when proteins were present in the same solution; reducing or preventing protein adsorption by PEGylating the MSNs hindered adsorption. Finally, the amount of miRNA adsorbed from human serum by MSN-NH2 was compared to a commercial miRNA purification kit (TaqMan®, Life Technologies, Carlsbad, CA, USA). MSN-NH2 adsorbed six times as much miRNA as the commercial kit, demonstrating higher sensitivity to subtle up- and downregulation of circulating miRNA in the blood of patients.